Please assess the completion status of the following clinical trial:

Trial Title: Pioglitazone as a Treatment for Lipid and Glucose Abnormalities In Patients With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients will be males or females, 18-70 yrs of age, with a diagnosis of schizophrenia or schizoaffective disorder, and currently being treated with olanzapine or clozapine.~2. Patients will have evidence of:~   1. glucose levels indicating at least impaired fasting glucose: fasting glucose 100 mg/dL or 2 hr glucose tolerance test 140 mg/dL, or current treatment with oral antidiabetic drugs with history of hyperglycemia;~  2. Triglyceride levels \> 120 mg/dL and/or HDL levels \< 40 mg/dL~Exclusion Criteria:~1. Diabetes mellitus, type 1~2. Recent diabetic ketoacidosis;~3. Patients not currently treated with oral antidiabetic drugs but fasting is glucose 140 mg/dL \[WHO criteria\] on repeat testing in last three months, or random blood glucose \>200 mg/dL plus 2 hr glucose on GTT \>200 mg/dL; (these patients may need more immediate treatment with antidiabetic drugs and it is less certain if weight-lifestyle treatment would be effective in treating such high glucose levels);~4. Patients with active liver disease with clinical abnormalities which need current treatment, or liver enzymes (Alt) 3 times upper limit for normal values in chart records in last year, or patients who are recorded as positive for hepatitis C;~5. Congestive heart failure (Class III or IV cardiac status) or history of MI in medical record (because pioglitazone can increase blood volume slightly);~6. Hematocrit greater than 10% below normal (hematocrit may be decreased 2 to 4% due to increased plasma volume);~7. Female patients on current oral contraceptives (because pioglitazone may interfere with effects of some oral contraceptives);~8. Patients taking ketoconazole,~9. Patients who have started on atorvastatin or gemfibrozil in the past 2 months or have had a dose increase in atorvastatin in the last month (since these drugs can also lower triglycerides and raise HDL, recent start of therapy with these drugs could be a confound).~10. Patients are not concomitantly treated with aripiprazole or ziprasidone.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Pioglitazone and life-style group (Type: ACTIVE_COMPARATOR): Pioglitazone (30-45 mg/daily) plus life-style diet group
- Placebo and life style group (Type: PLACEBO_COMPARATOR): Placebo capsules daily plus life-style diet group

Based on this trial design, predict the completion outcome and termination type (if applicable).